Revolution Medicines Dirección
Dirección controles de criterios 3/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Mark Goldsmith
Chief Executive Officer (CEO)
US$10.4m
Compensación total
| Porcentaje del salario del CEO | 6.1% |
| Permanencia del CEO | 10yrs |
| Participación del CEO | 0.4% |
| Permanencia media de la dirección | 6.5yrs |
| Promedio de permanencia en la Junta Directiva | 7.9yrs |
Actualizaciones recientes de la dirección
Recent updates
Calculating The Intrinsic Value Of Revolution Medicines, Inc. (NASDAQ:RVMD)
Sep 28
This Is Why Revolution Medicines, Inc.'s (NASDAQ:RVMD) CEO Compensation Looks Appropriate
Jun 15Revolution Medicines: On Hold Pending A Lower Entry Point
Jun 04Revolution Medicines: An Expensive Shot At A Massive Market Opportunity
Apr 12Revolution Medicines Is Hard To Understand
Feb 01Here's Why We're Not Too Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Situation
Aug 09Some Analysts Just Cut Their Revolution Medicines, Inc. (NASDAQ:RVMD) Estimates
May 13We Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business Growth
Apr 02We're Hopeful That Revolution Medicines (NASDAQ:RVMD) Will Use Its Cash Wisely
Dec 20We're Not Very Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Rate
Sep 15Revolution Medicines promotes Jack Anders to CFO
Sep 02New Forecasts: Here's What Analysts Think The Future Holds For Revolution Medicines, Inc. (NASDAQ:RVMD)
Aug 10Revolution Medicines to raise up to $200M in stock offering
Jul 19Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$519m |
| Mar 31 2024 | n/a | n/a | -US$484m |
| Dec 31 2023 | US$10m | US$631k | -US$436m |
| Sep 30 2023 | n/a | n/a | -US$331m |
| Jun 30 2023 | n/a | n/a | -US$296m |
| Mar 31 2023 | n/a | n/a | -US$259m |
| Dec 31 2022 | US$7m | US$607k | -US$249m |
| Sep 30 2022 | n/a | n/a | -US$245m |
| Jun 30 2022 | n/a | n/a | -US$224m |
| Mar 31 2022 | n/a | n/a | -US$208m |
| Dec 31 2021 | US$8m | US$581k | -US$187m |
| Sep 30 2021 | n/a | n/a | -US$169m |
| Jun 30 2021 | n/a | n/a | -US$143m |
| Mar 31 2021 | n/a | n/a | -US$126m |
| Dec 31 2020 | US$2m | US$554k | -US$110m |
| Sep 30 2020 | n/a | n/a | -US$95m |
| Jun 30 2020 | n/a | n/a | -US$85m |
| Mar 31 2020 | n/a | n/a | -US$71m |
| Dec 31 2019 | US$5m | US$504k | -US$62m |
| Sep 30 2019 | n/a | n/a | -US$57m |
| Dec 31 2018 | US$1m | US$490k | -US$49m |
Compensación vs. Mercado: La compensación total ($USD10.41M) de Mark está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD8.06M).
Compensación vs. Ingresos: La compensación de Mark ha aumentado mientras la empresa no es rentable.
CEO
Mark Goldsmith (62 yo)
10yrs
Permanencia
US$10,411,247
Compensación
Dr. Mark A. Goldsmith, M.D., Ph.D. is the Chief Executive Officer, President and Director of Revolution Medicines, Inc. since November 2014 and serves as its Chairman. Dr. Goldsmith served as a Venture Par...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Chairman | 10yrs | US$10.41m | 0.38% $ 34.6m | |
| Chief Financial Officer | 6.3yrs | US$3.05m | 0.029% $ 2.7m | |
| Chief Operating Officer | 6.1yrs | US$4.39m | 0.033% $ 3.0m | |
| President of Research & Development | 7.7yrs | US$4.39m | 0.11% $ 9.8m | |
| Executive Vice President of Development | 6.7yrs | US$3.23m | 0.015% $ 1.4m | |
| Co-Founder & Chairman of Scientific Advisory Board | no data | sin datos | sin datos | |
| Academic Co-Founder & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Academic Co-Founder & Member of Scientific Advisory Board | 7.9yrs | sin datos | sin datos | |
| Chief Information Officer | no data | sin datos | sin datos | |
| Chief Scientific Officer | 1.3yrs | sin datos | sin datos | |
| Senior Director of Corporate Communications & Investor Relations | no data | sin datos | sin datos | |
| Senior VP | 2.2yrs | sin datos | 0.0032% $ 299.1k |
6.5yrs
Permanencia media
53yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de RVMD es experimentado (6.5 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Chairman | 10yrs | US$10.41m | 0.38% $ 34.6m | |
| Co-Founder & Chairman of Scientific Advisory Board | no data | sin datos | sin datos | |
| Academic Co-Founder & Member of Scientific Advisory Board | 8.4yrs | sin datos | sin datos | |
| Academic Co-Founder & Member of Scientific Advisory Board | 7.9yrs | sin datos | sin datos | |
| Senior Advisor & Member of Scientific Advisory Board | 7.9yrs | sin datos | sin datos | |
| Lead Independent Director | 10yrs | US$510.63k | 1.4% $ 128.4m | |
| Senior Advisor & Member of Scientific Advisory Board | 8.4yrs | sin datos | sin datos | |
| Senior Advisor & Member of Scientific Advisory Board | 7.9yrs | sin datos | sin datos | |
| Independent Director | 2.3yrs | US$489.99k | 0.037% $ 3.4m | |
| Independent Director | 6.7yrs | sin datos | sin datos | |
| Independent Director | 9.7yrs | US$483.78k | 0.026% $ 2.4m | |
| Senior Advisor & Member of Scientific Advisory Board | 7.9yrs | sin datos | sin datos |
7.9yrs
Permanencia media
52yo
Promedio de edad
Junta con experiencia: La junta directiva de RVMD se considera experimentada (7.9 años de antigüedad promedio).